Immunophotonics Secures Initial $10 Million Series C Financing and Appoints Robert H. Arch, Ph.D., as President and CEO

Financing & CEO Transition Support Advancement of IP-001 Clinical Development and Strategic Growth Initiatives

SAINT LOUIS, MO, UNITED STATES, September 1, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immunostimulatory therapeutic approaches to enhance routine tumor ablation treatments, today announced that it had reached the milestone of closing $10 million in Series C financing. The financing is expected to support ongoing non-clinical and clinical development of IP-001, advancement of the company’s clinical Phase 2 programs, and other key corporate objectives as Immunophotonics works toward important clinical and regulatory milestones and future strategic opportunities. IP-001 is the company’s lead investigational drug candidate, which is currently being evaluated in clinical trials involving multiple solid tumor indications. The financing is expected to fund the company's planned operations through several anticipated clinical milestones and data readouts across its development programs.

Immunophotonics also announced a leadership transition effective September 1, 2026. Miguel Zubizarreta, who has served as Interim CEO since 2025, will step down from the Chief Executive Officer role and continue serving on the company’s Board of Directors. Robert Arch, Ph.D., currently President of Immunophotonics, has been promoted to the role of President and Chief Executive Officer. Dr. Arch brings more than two decades of experience in advancing immunotherapy programs from idea to clinical trials in biotechnology and multi-national pharma companies, including leadership roles spanning scientific research, business development, corporate strategy, and clinical development.

“This financing represents an important milestone for Immunophotonics and reflects the confidence of our shareholders in our science, strategy, and team. Closing an initial $10 million of Series C financing allows us to remain focused on the milestones we believe matter most: generating meaningful clinical data, advancing our development programs, and further evaluating the potential of IP-001 for patients with advanced solid tumors,” remarked Dr. Arch. “We are grateful for the continued support from our investors and look forward to working closely with our clinical and research partners as we advance our clinical strategy.”

Speaking on behalf of the Board, Immunophotonics Chairman Dr. Jonathan Knowles stated, “The Board is grateful for Miguel Zubizarreta’s leadership and contributions to Immunophotonics during an important fundraising period. We are delighted that he will continue to support the company as a member of the Board, providing valuable continuity as we enter this next stage under Robert Arch’s leadership.”

“I am proud of the progress Immunophotonics has achieved and the momentum it has gained over the past year,” added Miguel Zubizarreta. “Robert has partnered with me and other members of the Board in shaping our scientific and strategic direction, and I have great confidence in his ability to lead the company. I look forward to continuing to support the company and its mission as a member of the Board of Directors.”

About IP-001

IP-001 is a proprietary glycan polymer that generates tumor antigen depots and acts as a potent, multimodal immune stimulant intended to induce immunological responses to eradicate cancer. IP-001 is designed to (1) prolong the availability of tumor antigens liberated by tumor ablation, (2) facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) promote an adaptive immune response against the tumor cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumor cells throughout the body.

About Immunophotonics

Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology^®. IP-001, which is the first asset from the company’s intellectual property platform and is currently assessed in multiple clinical trials, has the potential to overcome the immunosuppressive milieu of the tumor microenvironment to enable a tumor-specific immune response in patients with solid cancers. By combining routine energy therapies, such as ablation or radiation, with injection of its proprietary immunostimulatory drug candidates, including IP-001, Immunophotonics seeks to trigger a systemically active anti-tumor immune response that can destroy circulating tumor cells and micro-metastases left behind after a local ablation. The company’s world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland. For more information, visit www.immunophotonics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law.

Immunophotonics Contact:
IR@immunophotonics.com

Public Relations
Immunophotonics, Inc.
email us here
Visit us on social media:
LinkedIn
Instagram
X